Labcorp (LH) said Monday it has made available the Labcorp Plasma Complete, a circulating tumor DNA-based test for patients with advanced solid tumors.
The test detects genomic alterations across 521 genes, including biomarkers associated with FDA-approved treatments.
The liquid biopsy test allows oncologists to profile patients from blood samples and draw up personalized treatments, the healthcare company said.
LH shares were 0.1% higher in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.